-->
Chapter 1. Methodology and Scope
1.1. Market Segmentation and Scope
1.2. Market Definitions
1.3. Research Methodology
1.3.1. Information Procurement
1.3.2. Information or Data Analysis
1.3.3. Market Formulation & Data Visualization
1.3.4. Data Validation & Publishing
1.4. Research Scope and Assumptions
1.4.1. List of Data Sources
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights
Chapter 3. Lung Cancer Diagnostics Market Variables, Trends, & Scope
3.1. Market Introduction/Lineage Outlook
3.2. Market Size and Growth Prospects (USD Million)
3.3. Market Dynamics
3.3.1. Market Drivers Analysis
3.3.2. Market Restraints Analysis
3.4. Lung Cancer Diagnostics Market Analysis Tools
3.4.1. Porter’s Analysis
3.4.1.1. Bargaining power of the suppliers
3.4.1.2. Bargaining power of the buyers
3.4.1.3. Threats of substitution
3.4.1.4. Threats from new entrants
3.4.1.5. Competitive rivalry
3.4.2. PESTEL Analysis
3.4.2.1. Political landscape
3.4.2.2. Economic and Social Landscape
3.4.2.3. Technological Landscape
3.4.2.4. Environmental Landscape
3.4.2.5. Legal Landscape
Chapter 4. Lung Cancer Diagnostics Market: Type Estimates & Trend Analysis
4.1. Segment Dashboard
4.2. Lung Cancer Diagnostics Market: Type Movement Analysis, 2025 & 2033
4.3. Non-small Cell Lung Cancer
4.3.1. Non-small Cell Lung Market Revenue Estimates and Forecasts,2024 - 2033
4.4. Small Cell Lung Cancer
4.4.1. Small Cell Lung Cancer Market Revenue Estimates and Forecasts,2024 - 2033
Chapter 5. Lung Cancer Diagnostics Market: Test Estimates & Trend Analysis
5.1. Segment Dashboard
5.2. Lung Cancer Diagnostics Market: Test Movement Analysis, 2025 & 2033
5.3. CA Tests
5.3.1. CA Tests Vision Market Revenue Estimates and Forecasts,2024 - 2033
5.4. HER2 Tests
5.4.1. HER2 Tests Vision Market Revenue Estimates and Forecasts,2024 - 2033
5.5. ALK Tests
5.5.1. ALK Tests Vision Market Revenue Estimates and Forecasts,2024 - 2033
5.6. Angiogenesis Inhibitors
5.6.1. Angiogenesis Inhibitors Vision Market Revenue Estimates and Forecasts,2024 - 2033
5.7. EGFR Mutation Tests
5.7.1. EGFR Mutation Tests Vision Market Revenue Estimates and Forecasts,2024 - 2033
5.8. KRAS Mutation Tests
5.8.1. KRAS Mutation Tests Vision Market Revenue Estimates and Forecasts,2024 - 2033
Chapter 6. Lung Cancer Diagnostics Market: End Use Estimates & Trend Analysis
6.1. Segment Dashboard
6.2. Lung Cancer Diagnostic Market: End Use Movement Analysis, 2025 & 2033
6.3. Hospitals and clinics
6.3.1. Hospitals and Clinics Market Revenue Estimates and Forecasts,2024 - 2033
6.4. Diagnostic Laboratories
6.4.1. Diagnostics Laboratories Market Revenue Estimates and Forecasts,2024 - 2033
6.5. Others
6.5.1. Others Market Revenue Estimates and Forecasts,2024 - 2033
Chapter 7. Lung Cancer Diagnostics Market: Regional Estimates & Trend Analysis
7.1. Lung Cancer Diagnostics Market Share, By Region, 2025 & 2033
7.2. North America
7.2.1. North America Lung Cancer Diagnostics Market Estimates and Forecasts,2024 - 2033
7.2.2. U.S.
7.2.2.1. U.S. Lung Cancer Diagnostics Market Estimates and Forecasts,2024 - 2033
7.2.3. Canada
7.2.3.1. Canada Lung Cancer Diagnostics Market Estimates and Forecasts,2024 - 2033
7.2.4. Mexico
7.2.4.1. Mexico Lung Cancer Diagnostics Market Estimates and Forecasts,2024 - 2033
7.3. Europe
7.3.1. Europe Lung Cancer Diagnostics Market Estimates and Forecasts,2024 - 2033
7.3.2. UK
7.3.2.1. UK Lung Cancer Diagnostics Market Estimates and Forecasts,2024 - 2033
7.3.3. Germany
7.3.3.1. Germany Lung Cancer Diagnostics Market Estimates and Forecasts,2024 - 2033
7.3.4. France
7.3.4.1. France Lung Cancer Diagnostics Market Estimates and Forecasts,2024 - 2033
7.4. Asia Pacific
7.4.1. Asia Pacific Lung Cancer Diagnostics Market Estimates and Forecasts,2024 - 2033
7.4.2. China
7.4.2.1. China Lung Cancer Diagnostics Market Estimates and Forecasts,2024 - 2033
7.4.3. Japan
7.4.3.1. Japan Lung Cancer Diagnostics Market Estimates and Forecasts,2024 - 2033
7.4.4. India
7.4.4.1. India Lung Cancer Diagnostics Market Estimates and Forecasts,2024 - 2033
7.4.5. South Korea
7.4.5.1. South Korea Lung Cancer Diagnostics Market Estimates and Forecasts,2024 - 2033
7.4.6. Australia
7.4.6.1. Australia Lung Cancer Diagnostics Market Estimates and Forecasts,2024 - 2033
7.5. Latin America
7.5.1. Latin America Lung Cancer Diagnostics Market Estimates and Forecasts,2024 - 2033
7.5.2. Brazil
7.5.2.1. Brazil Lung Cancer Diagnostics Market Estimates and Forecasts,2024 - 2033
7.6. Middle East and Africa
7.6.1. Middle East and Africa Lung Cancer Diagnostics Market Estimates and Forecasts,2024 - 2033
7.6.2. Saudi Arabia
7.6.2.1. Saudi Arabia Lung Cancer Diagnostics Market Estimates and Forecasts,2024 - 2033
7.6.3. UAE
7.6.3.1. UAE Lung Cancer Diagnostics Market Estimates and Forecasts,2024 - 2033
7.6.4. South Africa
7.6.4.1. South Africa Lung Cancer Diagnostics Market Estimates and Forecasts,2024 - 2033
Chapter 8. Competitive Landscape
8.1. Recent Developments & Impact Analysis by Key Market Participants
8.2. Company Categorization
8.3. Company Heat Map Analysis
8.4. Company Profiles
8.4.1. F. Hoffmann-La Roche Ltd
8.4.1.1. Participant’s Overview
8.4.1.2. Financial Performance
8.4.1.3. Product Benchmarking
8.4.1.4. Recent Developments/ Strategic Initiatives
8.4.2. Thermo Fisher Scientific
8.4.2.1. Participant’s Overview
8.4.2.2. Financial Performance
8.4.2.3. Product Benchmarking
8.4.2.4. Recent Developments/ Strategic Initiatives
8.4.3. Illumina Inc.
8.4.3.1. Participant’s Overview
8.4.3.2. Financial Performance
8.4.3.3. Product Benchmarking
8.4.3.4. Recent Developments/ Strategic Initiatives
8.4.4. Agilent Technologies
8.4.4.1. Participant’s Overview
8.4.4.2. Financial Performance
8.4.4.3. Product Benchmarking
8.4.4.4. Recent Developments/ Strategic Initiatives
8.4.5. Qiagen
8.4.5.1. Participant’s Overview
8.4.5.2. Financial Performance
8.4.5.3. Product Benchmarking
8.4.5.4. Recent Developments/ Strategic Initiatives
8.4.6. Abbott
8.4.6.1. Participant’s Overview
8.4.6.2. Financial Performance
8.4.6.3. Product Benchmarking
8.4.6.4. Recent Developments/ Strategic Initiatives
8.4.7. Bio-Rad
8.4.7.1. Participant’s Overview
8.4.7.2. Financial Performance
8.4.7.3. Product Benchmarking
8.4.7.4. Recent Developments/ Strategic Initiatives
8.4.8. Neogenomics Laboratories
8.4.8.1. Participant’s Overview
8.4.8.2. Financial Performance
8.4.8.3. Product Benchmarking
8.4.8.4. Recent Developments/ Strategic Initiatives
8.4.9. bioMérieux
8.4.9.1. Participant’s Overview
8.4.9.2. Financial Performance
8.4.9.3. Product Benchmarking
8.4.9.4. Recent Developments/ Strategic Initiatives
8.4.10. Myriad Genetics, Inc
8.4.10.1. Participant’s Overview
8.4.10.2. Financial Performance
8.4.10.3. Product Benchmarking
8.4.10.4. Recent Developments/ Strategic Initiatives
著作権 ©2022 無断複写・転載を禁じます